Alzheimer Research Center and Memory Clinic, Instituto Andaluz de Neurociencia (IANEC), Málaga, Spain.
Research Center and Memory Clinic, ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, Spain.
J Alzheimers Dis. 2024;98(2):601-618. doi: 10.3233/JAD-231150.
Microglial dysfunction plays a causative role in Alzheimer's disease (AD) pathogenesis. Here we focus on a germline insertion/deletion variant mapping SIRPβ1, a surface receptor that triggers amyloid-β(Aβ) phagocytosis via TYROBP.
To analyze the impact of this copy-number variant in SIRPβ1 expression and how it affects AD molecular etiology.
Copy-number variant proxy rs2209313 was evaluated in GERALD and GR@ACE longitudinal series. Hippocampal specimens of genotyped AD patients were also examined. SIRPβ1 isoform-specific phagocytosis assays were performed in HEK393T cells.
The insertion alters the SIRPβ1 protein isoform landscape compromising its ability to bind oligomeric Aβ and its affinity for TYROBP. SIRPβ1 Dup/Dup patients with mild cognitive impairment show an increased cerebrospinal fluid t-Tau/Aβ ratio (p = 0.018) and a higher risk to develop AD (OR = 1.678, p = 0.018). MRIs showed that Dup/Dup patients exhibited a worse initial response to AD. At the moment of diagnosis, all patients showed equivalent Mini-Mental State Examination scores. However, AD patients with the duplication had less hippocampal degeneration (p < 0.001) and fewer white matter hyperintensities. In contrast, longitudinal studies indicate that patients bearing the duplication allele show a slower cognitive decline (p = 0.013). Transcriptional analysis also shows that the SIRPβ1 duplication allele correlates with higher TREM2 expression and an increased microglial activation.
The SIRPβ1 internal duplication has opposite effects over MCI-to-Dementia conversion risk and AD progression, affecting microglial response to Aβ. Given the pharmacological approaches focused on the TREM2-TYROBP axis, we believe that SIRPβ1 structural variant might be considered as a potential modulator of this causative pathway.
小胶质细胞功能障碍在阿尔茨海默病(AD)发病机制中起因果作用。在这里,我们专注于一种种系插入/缺失变体映射 SIRPβ1,这是一种表面受体,通过 TYROBP 触发淀粉样蛋白-β(Aβ)吞噬作用。
分析该 SIRPβ1 表达的拷贝数变异体的影响,以及它如何影响 AD 的分子病因。
评估拷贝数变异体代理 rs2209313 在 GERALD 和 GR@ACE 纵向系列中的作用。还检查了基因分型 AD 患者的海马标本。在 HEK393T 细胞中进行 SIRPβ1 同工型特异性吞噬作用测定。
插入改变了 SIRPβ1 蛋白同工型的景观,损害了其结合寡聚体 Aβ的能力及其与 TYROBP 的亲和力。轻度认知障碍的 SIRPβ1Dup/Dup 患者表现出脑脊液 t-Tau/Aβ 比值升高(p=0.018),发生 AD 的风险更高(OR=1.678,p=0.018)。MRI 显示 Dup/Dup 患者对 AD 的初始反应更差。在诊断时,所有患者的 Mini-Mental State Examination 评分均相等。然而,携带重复的 AD 患者的海马体退化较少(p<0.001),且白质高信号更少。相比之下,纵向研究表明,携带重复等位基因的患者认知能力下降较慢(p=0.013)。转录分析还表明,SIRPβ1 重复等位基因与 TREM2 表达升高和小胶质细胞激活增加相关。
SIRPβ1 内部重复对 MCI 到痴呆转化风险和 AD 进展有相反的影响,影响小胶质细胞对 Aβ 的反应。鉴于针对 TREM2-TYROBP 轴的药物治疗方法,我们认为 SIRPβ1 结构变体可能被视为该致病途径的潜在调节剂。